Interview: Izana Tests GM-CSF Drug For Coronavirus
Compassionate Use Study Of Namilumab Starts In Italy
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
You may also be interested in...
GlaxoSmithKline is exploring a potential new way of tackling rheumatoid arthritis in just-started Phase III studies which could shake up a disease sector that is already attracting interest from other big pharma companies.
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.